Cue Biopharma reported positive results from a Phase 2 trial of its antibody CUE-221 in chronic spontaneous urticaria over the weekend, and the shares rose about 41 percent. The headline finding is that the drug cleared hives completely in a majority of patients at the two higher doses, a result that trade coverage read as a challenge to the market's incumbent biologic.
That reading is fair on the primary endpoint. The number that should decide how seriously to take the program is a different one, measured twelve weeks after the last dose.
What a hives patient runs out of
Chronic spontaneous urticaria is a condition in which hives and deep tissue swelling appear without an identifiable trigger, driven in many patients by autoantibodies that set off mast cells. It affects roughly one percent of people at some point, and for a minority it is severe, persistent and disruptive to sleep, work and daily life.
The treatment ladder has been stable for a decade. Second-generation antihistamines come first, with dosing pushed up to four times the label strength before the next step, and a substantial share of patients do not reach control even at that dose. Omalizumab, the anti-IgE antibody sold as Xolair, has been the preferred add-on since 2014 at 300 milligrams every four weeks. Cyclosporine sits behind it for refractory cases, carrying immunosuppression and the monitoring that comes with it. Dupilumab and the oral BTK inhibitor remibrutinib have joined more recently, and two drugs with different targets arriving within a few years of each other is the first real widening of the options since omalizumab was approved.
The sequence assumes each step works for someone and fails for someone else. What it does not offer is a stopping rule. Nothing in the ladder tells a clinician when a patient who is doing well can come off treatment, because the available drugs suppress the disease rather than resolve it, and the disease can outlast the prescription.
The incumbent's limitation is not that it fails to work. It is that it stops working when you stop taking it. Omalizumab achieves complete control in roughly 45 percent of antihistamine-refractory patients and leaves 40 to 55 percent still symptomatic, and it does not induce remission. Patients who respond generally stay on it, at roughly $30,000 a year in the United States before insurance, for as long as the disease persists.
The durability number is the interesting one
CUE-221's trial enrolled 145 patients whose hives were not controlled by antihistamines, across multiple centers in China. It was randomized, double-blind, and both placebo- and active-controlled: patients received one of three doses of CUE-221, placebo, or omalizumab 300 milligrams, with treatment running 16 weeks and follow-up extending to week 36.
At week 12, complete hive resolution was reported in 54 percent of patients at 4 milligrams per kilogram, 53 percent at 2, and 43 percent at 1, against 11 percent on placebo and 41 percent on omalizumab. The two higher doses reached statistical significance for the primary endpoint. Complete response on the composite UAS7 measure, the key secondary endpoint, was 46, 39 and 38 percent across the three doses against 11 percent on placebo and 29 percent on omalizumab.
Response deepened through week 22, when complete resolution reached 69 percent at the high dose. Then the interesting part: after the final dose at week 16, benefit held through week 28, twelve weeks off treatment, with 60 percent of high-dose patients still clear against 24 percent of those who had received omalizumab. A post hoc analysis put that gap at a statistically significant 36 percentage points.
If it holds up, that is a different product than the ones on the market. An anti-IgE that suppresses hives while it is infused is a maintenance therapy. An anti-IgE whose effect outlasts its presence in the body is closer to a disease-modifying one, and the difference shows up in what patients pay for and how often they have to sit for an injection.
The mechanism is the reason to believe it
CUE-221's design is what makes the durability finding more than noise. Omalizumab binds free IgE and pulls IgE receptors off the surface of mast cells and basophils, which is enough to stop the cells from firing as long as the antibody is around. CUE-221 targets the same molecule with an added mechanism: it also engages the CD23 pathway to reduce the production of new IgE, which is a step upstream.
Lowering the supply of new IgE, rather than only neutralizing what is already circulating, is the kind of intervention that could plausibly leave the disease less able to restart. The durability data are consistent with that hypothesis. They do not prove it, because the trial was not designed to test the mechanism, and an effect that persists after dosing can also reflect slow clearance of the antibody rather than a reset in the underlying biology.
The safety profile reported is clean and matters as much as the efficacy numbers in this class. No treatment-related serious adverse events, no anaphylaxis, infrequent injection-site reactions. Omalizumab carries a black box warning for anaphylaxis, which occurs in roughly one patient in a thousand, and any new entrant that avoids that label has a commercial advantage that has nothing to do with how well it clears hives.
What a stopping rule would be worth
The reason durability is the right thing to chase is that the current standard of care has no exit. Omalizumab is given indefinitely to the patients who respond, at monthly visits, and its label carries the anaphylaxis warning that requires observation after each dose. Patients who achieve complete control on it are, in practice, patients who stay on it. Some do go into spontaneous remission and stop, but physicians have no reliable way to identify them in advance, so the decision to discontinue is made on a trial basis and reversed if the hives return.
A drug that produces a durable response after a defined course inverts that. Instead of a monthly appointment that continues until the disease resolves on its own, treatment becomes an episode with an endpoint. The commercial implications cut against the company's short-term interest and are worth naming for that reason: a finite course generates less revenue per patient than an indefinite one, which is an unusual claim for a biotech to lead with. It produces a stronger argument to payers, who currently absorb years of biologic spending for a condition that is not life-threatening and who have reason to prefer a treatment that ends.
The clinical value turns on a question the trial did not answer. If hives stay away after the drug clears, does that mean the underlying autoantibody drive has quieted, or that the antibody's own slow elimination is still doing the work? A week 28 measurement sits close enough to the last dose that the two explanations are not fully separable from the data reported, and the only way to tell them apart is to follow patients for considerably longer than this trial did.
The comparison that was not powered
Here is where the enthusiasm needs tempering. Omalizumab's arm was included for comparative efficacy, not for statistical testing. The trial was not built to demonstrate that CUE-221 beats it, and none of the headline comparisons against omalizumab carry the weight of a designed head-to-head analysis. The week 28 result, which is the most commercially meaningful number in the dataset, is explicitly post hoc.
That distinction is not pedantry, because the anti-IgE class has already produced one expensive lesson about drawing conclusions against this particular comparator. Ligelizumab, a next-generation anti-IgE designed to bind IgE more tightly, went through large trials and failed to beat omalizumab, leaving its developer with a program it could not advance. A better antibody on paper did not translate into a better drug in patients, and every subsequent durability or superiority claim inherits that caution.
Cue's own framing has been appropriately narrow. The company describes the post hoc durability advantage as a signal and has said the data do not establish superiority, which is the correct position for a dataset of this size and structure.
Data from China, rights everywhere else
The commercial structure behind the result is worth understanding, because it shapes what happens next. The trial was run in China by Genesis Life Sciences, which holds rights there, in Hong Kong, Macau and Taiwan, under the name UB-221. Cue licensed the ex-China rights from Ascendant Health Sciences in April for $15 million up front and up to $676.5 million in milestones, which means the company's entire equity story now rests on a partner's trial in a population and regulatory system that are not the ones a US approval would depend on.
That is a real constraint on the timeline, and not only a matter of paperwork. A US program requires its own trial conduct under FDA standards, ordinarily with a population that reflects the patients who will receive the drug, and a single-region dataset raises questions about whether the effect size travels. Cue has said it plans a Phase 2b/3 study in urticaria along with a Phase 2 in food allergy. Neither has a stated start date, and the company has not yet said what the durability finding means for how long a confirmatory trial should run. That design question is the one its own data raise: a twelve-week endpoint cannot detect a difference that shows up after the drug is withdrawn, and a trial built to confirm a maintenance effect would miss the thing that makes this drug interesting.
Chronic hives has been a profitable market to challenge and an unforgiving one. The incumbent is dosed monthly, works in about half of the patients who need it, and costs more than most patients realize because insurers absorb most of it. Beating it on complete resolution in a well-run trial would be a strong result. Beating it on how long patients stay clear after stopping is a better one, and the trial that could establish it has not been designed yet.
Primary sources
- Fierce Biotech for the trial design, dose arms, and the company's characterization of the durability result as a signal rather than established superiority.
- Nasdaq for the efficacy figures at week 12, week 22 and week 28, and the post hoc comparison against omalizumab.
- Dermatology Advisor for the chronic spontaneous urticaria treatment ladder, omalizumab's complete response rate and absence of long-term remission, the remibrutinib and dupilumab options, and the ligelizumab failure against omalizumab.
- Yahoo Finance for the share move and licensing terms.